Agenus Inc. (AGEN)
Largest Insider Buys in Sector
AGEN Stock Price History Chart
AGEN Stock Performance
About Agenus Inc.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Insider Activity of Agenus Inc.
Over the last 12 months, insiders at Agenus Inc. have bought $324,050 and sold $0 worth of Agenus Inc. stock.
On average, over the past 5 years, insiders at Agenus Inc. have bought $171,525 and sold $1.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ARMEN GARO H (See Remarks) — $648,100.
The last purchase of 500,000 shares for transaction amount of $324,050 was made by ARMEN GARO H (See Remarks) on 2024‑02‑15.
List of Insider Buy and Sell Transactions, Agenus Inc.
| 2024-02-15 | See Remarks | 500,000 0.0915% | $0.65 | $324,050 | -48.74% | |||
| 2023-11-15 | director | 25,000 0.0067% | $0.76 | $19,000 | -20.20% | |||
| 2022-01-06 | Sale | Chief Medical Officer | 38,679 0.0149% | $3.06 | $118,346 | -16.94% | ||
| 2021-09-13 | Sale | Chairman and CEO | 82,107 0.0357% | $6.50 | $533,696 | -56.93% | ||
| 2021-09-10 | Sale | PFO & PAO | 11,120 0.0047% | $6.50 | $72,280 | -57.69% | ||
| 2020-06-17 | Sale | 10 percent owner | 283,840 0.1709% | $3.66 | $1.04M | +4.04% | ||
| 2020-06-16 | Sale | 10 percent owner | 144,160 0.0877% | $3.66 | $528,015 | +4.63% | ||
| 2020-06-15 | Sale | 10 percent owner | 384,025 0.2247% | $3.57 | $1.37M | +3.05% | ||
| 2020-06-12 | Sale | 10 percent owner | 9,100 0.0055% | $3.58 | $32,556 | +6.30% | ||
| 2020-06-11 | Sale | 10 percent owner | 183,875 0.1139% | $3.77 | $692,786 | +3.20% | ||
| 2017-12-12 | Sale | Chief Legal Officer | 16,716 0.0174% | $3.46 | $57,842 | -16.91% | ||
| 2017-12-12 | Sale | VP, Finance | 11,220 0.0117% | $3.46 | $38,836 | -16.91% | ||
| 2017-12-12 | Sale | Chief Commercial Officer | 7,424 0.0077% | $3.46 | $25,691 | -16.91% | ||
| 2017-12-12 | Sale | Chief Communications Officer | 7,022 0.0073% | $3.46 | $24,304 | -16.91% | ||
| 2017-12-12 | Sale | Chief Technology Officer | 13,092 0.0137% | $3.46 | $45,302 | -16.91% | ||
| 2017-10-30 | Chairman & CEO | 80,776 0.0835% | $3.61 | $291,706 | -2.11% | |||
| 2017-10-27 | Chairman & CEO | 119,224 0.1159% | $3.51 | $418,524 | -5.18% | |||
| 2017-04-12 | Chairman & CEO | 58,912 0.0604% | $3.29 | $194,109 | +18.52% | |||
| 2017-04-10 | Chairman & CEO | 141,088 0.1464% | $3.37 | $474,930 | +16.21% | |||
| 2017-02-14 | 10 percent owner | 20M 29.1662% | $6.00 | $120M | -14.32% |
Insider Historical Profitability
| ARMEN GARO H | See Remarks | 625969 2.6684% | $3.07 | 26 | 6 | +16.59% |
| INCYTE CORP | 10 percent owner | 16972968 72.3519% | $3.07 | 1 | 5 | <0.0001% |
| QVT Associates GP LLC | 10 percent owner | 6915630 29.4798% | $3.07 | 0 | 1 | |
| WIINBERG ULF | director | 124063 0.5289% | $3.07 | 2 | 0 | <0.0001% |
| Valentine Karen | Chief Legal Officer | 101521 0.4328% | $3.07 | 0 | 15 | |
| KLASKIN CHRISTINE M | PFO & PAO | 93056 0.3967% | $3.07 | 0 | 16 | |
| Sharp Shalini | director | 81311 0.3466% | $3.07 | 2 | 15 | +24.13% |
| HATSOPOULOS JOHN | director | 65000 0.2771% | $3.07 | 3 | 0 | +179.69% |
| O'Day Steven J | Chief Medical Officer | 61321 0.2614% | $3.07 | 0 | 1 | |
| Baysal Ozer | Chief Commercial Officer | 58790 0.2506% | $3.07 | 1 | 1 | +35.69% |
| Wentworth Kerry | VP, Clinical, Reg & Qual | 57410 0.2447% | $3.07 | 0 | 16 | |
| Buell Jennifer | Chief Communications Officer | 35656 0.152% | $3.07 | 0 | 1 | |
| Duncan Alex | Chief Technology Officer | 21026 0.0896% | $3.07 | 0 | 1 | |
| MARGARET EISEN | director | 20000 0.0853% | $3.07 | 2 | 0 | +21.26% |
| Ballantyne Charles Evan | Chief Financial Officer | 10000 0.0426% | $3.07 | 1 | 0 | <0.0001% |
| Wright Timothy | director | 10000 0.0426% | $3.07 | 1 | 0 | <0.0001% |
| Thornton Peter | CFO & Sr. VP | 5000 0.0213% | $3.07 | 1 | 0 | +22.52% |
| SRIVASTAVA PRAMOD | director | 1610 0.0069% | $3.07 | 0 | 1 | |
| ATLEE FRANK V III | director | 0 0% | $3.07 | 0 | 1 | |
| AFEYAN NOUBAR | director | 0 0% | $3.07 | 0 | 1 | |
| Malik Shahzad | director | 0 0% | $3.07 | 0 | 2 |
Institutional Investor Ownership
| The Vanguard Group | $19.95B | 163.82 | 34.4M | +13.66% | +$2.4B | 0.37 | |
| Deep Track Capital Lp | $18.38B | 150.95 | 31.7M | 0% | +$0 | 84.33 | |
| Point72 Asset Management | $17.47B | 143.4 | 30.11M | +151.26% | +$10.51B | 25.54 | |
| BlackRock | $16.96B | 139.29 | 29.25M | -9.27% | -$1.73B | 0.37 | |
| Artal Group S A | $9.07B | 74.44 | 15.63M | 0% | +$0 | 39.62 | |
| Geode Capital Management | $4.7B | 38.57 | 8.1M | +2.43% | +$111.4M | 0.4 | |
| State Street | $4.32B | 35.49 | 7.45M | -14.15% | -$712.19M | 0.18 | |
| Renaissance Technologies | $3.14M | 25.79 | 5.42M | -10.25% | -$358,832.90 | 0.01 | |
| Goldman Sachs | $38.11M | 15.64 | 3.29M | +13.53% | +$4.54M | 0.01 | |
| D. E. Shaw & Co. | $1.9B | 15.62 | 3.28M | +7.88% | +$138.96M | 1.83 | |
| Northern Trust | $1.83B | 15.05 | 3.16M | -9.23% | -$186.47M | 0.3 | |
| Millennium Management LLC | $1.55B | 12.72 | 2.67M | -68.14% | -$3.31B | 1 | |
| Morgan Stanley | $1.52B | 12.51 | 2.63M | +1.5% | +$22.45M | 0.11 | |
| Charles Schwab | $1.41B | 11.6 | 2.44M | -10.89% | -$172.62M | 0.31 | |
| Wellington Management Company | $1.33B | 10.94 | 2.3M | New | +$1.33B | 0.23 | |
| BNY Mellon | $804.12M | 6.6 | 1.39M | -6.36% | -$54.65M | 0.15 | |
| Bank of America | $776.41M | 6.38 | 1.34M | +0.08% | +$593,919.04 | 0.08 | |
| Gsa Capital Partners Llp | $737,000.00 | 6.05 | 1.27M | -47.04% | -$654,500.33 | 0.06 | |
| Panagora | $712.71M | 5.85 | 1.23M | +7.57% | +$50.15M | 3.57 | |
| AQR Capital | $689.81M | 5.66 | 1.19M | +157.66% | +$422.1M | 1.08 | |
| Nuveen | $665.98M | 5.47 | 1.15M | 0% | +$0 | 0.19 | |
| Oracle Investment Management Inc | $618.84M | 5.08 | 1.07M | -24.7% | -$203M | 83.36 | |
| Wells Fargo | $562.69M | 4.62 | 970,150 | -4.06% | -$23.84M | 0.15 | |
| Key Client Fiduciary Advisors Llc | $498.2M | 4.09 | 858,969 | New | +$498.2M | 74.26 | |
| Acadian Asset Management | $439,000.00 | 3.61 | 757,397 | +1,959.93% | +$417,688.65 | <0.01 | |
| Two Sigma | $356.39M | 2.93 | 614,463 | -48.93% | -$341.45M | 0.54 | |
| Fidelity Investments | $355.14M | 2.92 | 612,313 | -1.89% | -$6.85M | 0.02 | |
| Franklin Templeton Investments | $318.77M | 2.62 | 549,608 | +236.31% | +$223.99M | 0.1 | |
| RhumbLine Advisers | $317.03M | 2.6 | 546,623 | +4.55% | +$13.81M | 0.29 | |
| UBS | $310.08M | 2.55 | 534,621 | -7.72% | -$25.94M | 0.09 | |
| Susquehanna International Group | $303.35M | 2.49 | 523,017 | -12.56% | -$43.56M | 0.3 | |
| Exchange Traded Concepts, LLC | $275.57M | 2.26 | 475,130 | +343.97% | +$213.5M | 6.26 | |
| Pennant Capital Management Llc | $272.37M | 2.24 | 469,600 | 0% | +$0 | 43.04 | |
| Tudor Investment Corp Et Al | $217.86M | 1.79 | 375,627 | 0% | +$0 | 2.33 | |
| Connor Clark & Lunn Investment Management Ltd | $216.15M | 1.78 | 372,671 | New | +$216.15M | 0.47 | |
| T. Rowe Price | $208,000.00 | 1.7 | 357,915 | +52.4% | +$71,514.37 | <0.0001 | |
| Voya Investment Management LLC | $201.7M | 1.66 | 347,764 | +18.94% | +$32.12M | 0.22 | |
| Values First Advisors, Inc. | $194.94M | 1.6 | 336,100 | +24.56% | +$38.44M | 43.19 | |
| State of Wisconsin Investment Board | $175.97M | 1.45 | 303,400 | +894.79% | +$158.28M | 0.46 | |
| Barclays | $167,000.00 | 1.38 | 289,401 | -52.56% | -$185,005.24 | <0.0001 | |
| Jane Street Capital | $159.92M | 1.31 | 275,730 | -75.62% | -$496.15M | 0.15 | |
| AllianceBernstein | $147.91M | 1.21 | 255,010 | 0% | +$0 | 0.05 | |
| Powell Investment Advisors LLC | $141.23M | 1.16 | 243,500 | +21.75% | +$25.23M | 42.82 | |
| CAPTRUST | $129.29M | 1.06 | 222,915 | +17.82% | +$19.56M | 0.11 | |
| American International Group | $108.93M | 0.89 | 187,814 | -0.85% | -$935,538.97 | 0.37 | |
| Los Angeles Capital Management LLC | $101.66M | 0.84 | 175,272 | -12.72% | -$14.81M | 0.33 | |
| Deutsche Bank | $96.83M | 0.8 | 166,954 | -7.07% | -$7.36M | 0.04 | |
| Group One Trading | $96.46M | 0.79 | 166,309 | -42.51% | -$71.32M | 1.28 | |
| Invesco | $91.56M | 0.75 | 157,859 | +4.42% | +$3.87M | 0.02 | |
| JPMorgan Chase | $89.77M | 0.74 | 154,778 | -38.6% | -$56.44M | 0.01 |